
...

By Nick Mordowanec
Staff Writer
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Early clinical and preclinical results are showing that experimental mRNA and nanoparticle vaccines produced measurable immune responses against pancreatic cancer, one of the deadliest cancers, and that in small patient groups those immune responses correlated with delayed recurrence or prolonged survival.
Why It Matters
Pancreatic cancer has among the lowest survival rates of common cancers and limited effective treatments. Multiple small trials and preclinical studies published and reported in the past year indicated that novel vaccine platforms, including personalized mRNA vaccines and layered lipid nanoparticles, were able to induce tumor‑targeting T cells in patients and animal models, prompting researchers to plan larger trials.
Read More on U.S.
Pancreatic ductal adenocarcinoma had an approximate five‑year survival near 13 percent in recent reports, making it one of the most lethal common cancers.
What To Know
Researchers at Memorial Sloan Kettering (MSK) and collaborators ran a phase 1 trial in February testing a personalized mRNA vaccine called autogene cevumeran (BNT122, RO7198457) in 16 patients with operable pancreatic cancer who received surgery, chemotherapy and the vaccine, according to the peer reviewed journal Nature Medicine.
Vinod Balachandran, a surgical oncologist at MSK, was the principal investigator of the February 2025 trial. He's also the director of the Olayan Center for Cancer Vaccines at the MSK Cancer Center.
"Our phase I study showed these personalized immunotherapies are safe and can trigger an immune response that correlates with improved outcomes in patients with surgically removable pancreatic cancer," Balachandran told Newsweek via email on Monday. "This initial trial was early phase and requires validation in a larger group of patients."
A global randomized phase II study is "ongoing," he added, which is comparing the efficacy of these personalized immunotherapies with standard-of-care chemotherapy in patients with pancreatic cancer.
The vaccine was developed and researched through a collaboration between BioNTech, an immunotherapy company, and Genentech, a member of the Roche Group. It is not a cure for the type of cancer itself; however, signs point to improving longevity in individuals who contract the disease.
Investigators reported that half of participants mounted vaccine‑induced tumor‑specific T‑cell responses. Also, long-term efficacy was reported as patients with a vaccine-induced immune response had a reduced risk of cancer returning at three-year follow-up appointments compared with patients whose immune systems did not respond.
Trials have occurred as cancer is on the rise this year compared to last, according to the American Cancer Society's 2025 annual Facts & Figures report.
More than 2 million new cancer cases are expected this year, according to a 48-page report. Roughly 618,000 Americans are expected to die from cancer in 2025, equating to about 1,700 deaths per day, and both one-in-three men and women are said to develop cancer in their lifetime.
These five cancers are predicted to take nearly 323,900 male lives in a year:
- Lung and bronchus—64,190 male deaths
- Prostate—35,770 male deaths
- Colon and rectum—28,900 male deaths
- Pancreas—27,050 male deaths
- Liver and intrahepatic bile duct—19,250 male deaths
These five cancers are estimated to take nearly 294,220 female lives in a year, described by researchers as a "substantial" increase compared to 2024 numbers:
- Lung and bronchus—60,540 female deaths
- Breast—42,170 female deaths
- Pancreas—24,930 female deaths
- Colon and rectum—24,000 female deaths
- Uterine—13,860 female deaths

...
What People Are Saying
Vinod Balachandran said at the time of the trial's conclusion: "The latest data from the phase 1 trial are encouraging. They suggest this investigational therapeutic mRNA vaccine can mobilize anti-tumor T cells that may recognize pancreatic cancers as foreign, potentially years after vaccination."
He added: "For patients with pancreatic cancer, our latest results continue to support the approach of using personalized mRNA vaccines to target neoantigens in each patient's tumor. If you can do this in pancreas cancer, theoretically you may be able to develop therapeutic vaccines for other cancer types."
Immunologist Li Lily Wang, an associate professor of molecular medicine at the Case Western Reserve School of Medicine, said earlier this year: "This platform has the potential to transform clinical care for this devastating disease. I am excited to see that our novel nano-vaccine worked so well in eliciting vigorous responses from tumor-reactive T cells-which are typically low in numbers and unable to control tumor growth."
What Happens Next?
Across studies, authors and outside experts urged caution because the human data remained small. Investigators and commentators said larger randomized trials were necessary to determine whether the immune responses would translate into durable survival benefits and acceptable safety in broader patient populations.
Update 8/11/25, 5:20 p.m. ET: This article has been updated with comment from Balachandran.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines